181 related articles for article (PubMed ID: 35768853)
1. Primary cold atmospheric plasma combined with low dose cisplatin as a possible adjuvant combination therapy for HNSCC cells-an in-vitro study.
Brunner TF; Probst FA; Troeltzsch M; Schwenk-Zieger S; Zimmermann JL; Morfill G; Becker S; Harréus U; Welz C
Head Face Med; 2022 Jun; 18(1):21. PubMed ID: 35768853
[TBL] [Abstract][Full Text] [Related]
2. Cold Atmospheric Plasma: A Promising Complementary Therapy for Squamous Head and Neck Cancer.
Welz C; Emmert S; Canis M; Becker S; Baumeister P; Shimizu T; Morfill GE; Harréus U; Zimmermann JL
PLoS One; 2015; 10(11):e0141827. PubMed ID: 26588072
[TBL] [Abstract][Full Text] [Related]
3. Zerumbone acts as a radiosensitizer in head and neck squamous cell carcinoma.
Schnoell J; Stanisz I; Jank BJ; Stanek V; Schmid R; Brunner M; Heiduschka G; Kotowski U
Invest New Drugs; 2022 Apr; 40(2):224-231. PubMed ID: 34613571
[TBL] [Abstract][Full Text] [Related]
4. Cold atmospheric plasma treatment selectively targets head and neck squamous cell carcinoma cells.
Guerrero-Preston R; Ogawa T; Uemura M; Shumulinsky G; Valle BL; Pirini F; Ravi R; Sidransky D; Keidar M; Trink B
Int J Mol Med; 2014 Oct; 34(4):941-6. PubMed ID: 25050490
[TBL] [Abstract][Full Text] [Related]
5. Use of Cold Atmospheric Plasma in the Treatment of Squamous Cell Carcinoma: in vitro Effects and Clinical Application in Feline Tumors: A Pilot Study.
Holanda AGA; Cesário BC; Silva VM; Francelino LEC; Nascimento BHM; Damasceno KFA; Ishikawa U; Farias NBS; Junior RFA; Barboza CAG; Junior CA; Antunes JMAP; Moura CEB; Queiroz GF
Top Companion Anim Med; 2023; 53-54():100773. PubMed ID: 36990177
[TBL] [Abstract][Full Text] [Related]
6. The ATR inhibitor berzosertib acts as a radio- and chemosensitizer in head and neck squamous cell carcinoma cell lines.
Schnoell J; Sparr C; Al-Gboore S; Haas M; Brkic FF; Kadletz-Wanke L; Heiduschka G; Jank BJ
Invest New Drugs; 2023 Dec; 41(6):842-850. PubMed ID: 37934325
[TBL] [Abstract][Full Text] [Related]
7. Over-expression of BAG-1 in head and neck squamous cell carcinomas (HNSCC) is associated with cisplatin-resistance.
Liu S; Ren B; Gao H; Liao S; Zhai YX; Li S; Su XJ; Jin P; Stroncek D; Xu Z; Zeng Q; Li Y
J Transl Med; 2017 Sep; 15(1):189. PubMed ID: 28877725
[TBL] [Abstract][Full Text] [Related]
8. Simvastatin suppresses head and neck squamous cell carcinoma ex vivo and enhances the cytostatic effects of chemotherapeutics.
Stoehr M; Mozet C; Boehm A; Aigner A; Dietz A; Wichmann G
Cancer Chemother Pharmacol; 2014 Apr; 73(4):827-37. PubMed ID: 24562588
[TBL] [Abstract][Full Text] [Related]
9. Combinatorial Effect of Cold Atmosphere Plasma (CAP) and the Anticancer Drug Cisplatin on Oral Squamous Cell Cancer Therapy.
Lee CM; Jeong YI; Kook MS; Kim BH
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33076565
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin overcomes radiotherapy resistance in OCT4-expressing head and neck squamous cell carcinoma.
Routila J; Qiao X; Weltner J; Rantala JK; Carpén T; Hagström J; Mäkitie A; Leivo I; Ruuskanen M; Söderlund J; Rintala M; Hietanen S; Irjala H; Minn H; Westermarck J; Ventelä S
Oral Oncol; 2022 Apr; 127():105772. PubMed ID: 35245886
[TBL] [Abstract][Full Text] [Related]
11. The Polo-like kinase 1 inhibitor onvansertib represents a relevant treatment for head and neck squamous cell carcinoma resistant to cisplatin and radiotherapy.
Hagege A; Ambrosetti D; Boyer J; Bozec A; Doyen J; Chamorey E; He X; Bourget I; Rousset J; Saada E; Rastoin O; Parola J; Luciano F; Cao Y; Pagès G; Dufies M
Theranostics; 2021; 11(19):9571-9586. PubMed ID: 34646387
[No Abstract] [Full Text] [Related]
12. Cancer stem cell mediated acquired chemoresistance in head and neck cancer can be abrogated by aldehyde dehydrogenase 1 A1 inhibition.
Kulsum S; Sudheendra HV; Pandian R; Ravindra DR; Siddappa G; R N; Chevour P; Ramachandran B; Sagar M; Jayaprakash A; Mehta A; Kekatpure V; Hedne N; Kuriakose MA; Suresh A
Mol Carcinog; 2017 Feb; 56(2):694-711. PubMed ID: 27380877
[TBL] [Abstract][Full Text] [Related]
13. Cellular pharmacokinetic/pharmacodynamic relationship of platinum cytostatics in head and neck squamous cell carcinoma evaluated by liquid chromatography coupled to tandem mass spectrometry.
Theile D; Detering JC; Herold-Mende C; Dyckhoff G; Haefeli WE; Weiss J; Burhenne J
J Pharmacol Exp Ther; 2012 Apr; 341(1):51-8. PubMed ID: 22207655
[TBL] [Abstract][Full Text] [Related]
14. Targeting Wee1 kinase to suppress proliferation and survival of cisplatin-resistant head and neck squamous cell carcinoma.
Yang Z; Liao J; Lapidus RG; Fan X; Mehra R; Cullen KJ; Dan H
Cancer Chemother Pharmacol; 2022 Apr; 89(4):469-478. PubMed ID: 35212780
[TBL] [Abstract][Full Text] [Related]
15. VE-822 Enhanced Cisplatin Chemotherapy Effects on Head and Neck Squamous Cell Carcinoma Drug-resistant Cells.
Chen T; Yang F; Dai X; Yu Y; Sun Y; Wu X; Li R; Zhou Q
Curr Cancer Drug Targets; 2023; 23(6):482-495. PubMed ID: 36748213
[TBL] [Abstract][Full Text] [Related]
16. Regulation of excision repair cross-complementation group 1 by Snail contributes to cisplatin resistance in head and neck cancer.
Hsu DS; Lan HY; Huang CH; Tai SK; Chang SY; Tsai TL; Chang CC; Tzeng CH; Wu KJ; Kao JY; Yang MH
Clin Cancer Res; 2010 Sep; 16(18):4561-71. PubMed ID: 20823140
[TBL] [Abstract][Full Text] [Related]
17. Synergistic antitumor effect of AAV-mediated TRAIL expression combined with cisplatin on head and neck squamous cell carcinoma.
Jiang M; Liu Z; Xiang Y; Ma H; Liu S; Liu Y; Zheng D
BMC Cancer; 2011 Feb; 11():54. PubMed ID: 21291526
[TBL] [Abstract][Full Text] [Related]
18. Combination Treatment of Withalongolide a Triacetate with Cisplatin Induces Apoptosis by Targeting Translational Initiation, Migration, and Epithelial to Mesenchymal Transition in Head and Neck Squamous Cell Carcinoma.
Subramanian C; Spielbauer KK; Pearce R; Kovatch KJ; Prince ME; Timmermann BN; Cohen MS
Nutrients; 2022 Dec; 14(24):. PubMed ID: 36558560
[TBL] [Abstract][Full Text] [Related]
19. Cold atmospheric plasma sensitizes head and neck cancer to chemotherapy and immune checkpoint blockade therapy.
Wang Y; Mang X; Li D; Wang Z; Chen Y; Cai Z; Tan F
Redox Biol; 2024 Feb; 69():102991. PubMed ID: 38103343
[TBL] [Abstract][Full Text] [Related]
20. Silencing of high-mobility group box 2 (HMGB2) modulates cisplatin and 5-fluorouracil sensitivity in head and neck squamous cell carcinoma.
Syed N; Chavan S; Sahasrabuddhe NA; Renuse S; Sathe G; Nanjappa V; Radhakrishnan A; Raja R; Pinto SM; Srinivasan A; Prasad TS; Srikumar K; Gowda H; Santosh V; Sidransky D; Califano JA; Pandey A; Chatterjee A
Proteomics; 2015 Jan; 15(2-3):383-93. PubMed ID: 25327479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
